The Tytgat group focuses on translational studies in pediatric solid tumors. By implementing liquid biopsies, we aim to improve the diagnostic sensitivity, to better monitor response to therapy and predict which patient is clear from tumor and which patient is at risk for recurrent disease.
The Tytgat Group is looking for an enthusiastic, highly motivated postdoctoral researcher in possession of an article 9 diploma and Experience with Flow Cytometry and in vivo studies is essential.
The Tytgat Group
The overall aim of our group is to translate basic findings to the clinic. The Tytgat group has several translational projects on pediatric Neuroblastoma, in the Princess Máxima Center for Pediatric Oncology, the Dutch national hospital for childhood cancer. This institute has the ambition to cure every child with cancer, while providing optimal quality of life. Hereto, scientific research and clinical care are closely integrated, providing a unique opportunity for translational research. In our group, we apply innovative single-cell technology, flow cytometry, and sequencing of samples of pediatric patients. We collaborate closely with disease-oriented groups within the Princess Máxima Center and internationally with other groups studying pediatric solid tumors. Core values in our group are collaboration, curiosity and clinical impact.
The project:
Despite the promise of immunotherapy in adult cancers, for many pediatric solid tumors, such as neuroblastoma, immunotherapies are not yet so successful. Neuroblastoma is a rare form of cancer that predominantly affects young children and has a high mortality rate. In order to study the potential barriers and optimal immunotherapy approaches, in this unique project we have formed a collaboration between the Princess Máxima Center, Tytgat and Molenaar group and Sanquin Amsterdam, Amsen group. Multiple immunotherapies to treat neuroblastoma are under development, but a reliable preclinical system to test and improve these is lacking. For that purpose, we will develop a system in which the human immune response to neuroblastoma can be studied in vivo.
We are looking for an energetic postdoc in possession of an article 9 diploma. Experience with Flow Cytometry and in vivo studies is essential. Affinity with bioinformatics and especially single cell RNAsequence data analysis is a plus.
We offer
We offer 1,5 years of funding (with potential for extension) in a vibrant international multidisciplinary scientific environment. This is a collaborative project between Dr. Lieve Tytgat and Jan Molenaar (Cancers 2021 13(9):2096; J Immunother Cancer. 2021 e002259; Eur J Cancer 2021 144:123-150) at the Princes Maxima center, and Dr. Derk Amsen at Sanquin (f.i. Nature Immunol. 2018,19: 538; Immunity 2018,5:1046; Nature Immunol. 2016,17:1467; Nature Immunol.2014,15:1143). Although primary appointment will be at the Princess Máxima Center, the experimental work will be conducted at Sanquin. The postdoc will work closely with a technician and be embedded in a strong and collaborative community working on T cells (5 group leaders, 25+ students, postdocs and technicians) at Sanquin as well as a very active research community in the Princes Maxima center, with 35 research groups.
The position is based on 32 – 36 hours per week. Salary is based on postdoc salary FWG 60 depending on years of experience. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.
Are you excited about this position?
You can apply for this position until by pressing the “apply” button on this screen. Please including motivation letter, CV as well as names and contact information of at least 2 references – all documents within a single PDF file.
For more information about the vacancy, you are welcome to contact Dr. Lieve Tytgat (g.a.m.tytgat@prinsesmaximacentrum.nl) or Dr. Derk Amsen (d.amsen@sanquin.nl).
Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.
Solliciteer direct